Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1850 of 2026 entries
View as:

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

Phase: N/A Priority: Normal
NCT ID: NCT01059682 Org: User:
Start: 01/31/10 End: 09/30/11 Due: 09/30/12

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

Phase: N/A Priority: Normal
NCT ID: NCT03842969 Org: User:
Start: 04/23/19 End: 03/30/22 Due: 03/30/23

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Phase: N/A Priority: Normal
NCT ID: NCT05271409 Org: User:
Start: 08/30/22 End: 12/31/28 Due: 12/31/29

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04857138 Org: User:
Start: 05/18/21 End: 01/18/24 Due: 01/18/25

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00002314 Org: User:
Start: - End: - Due: -

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02694536 Org: User:
Start: 08/01/06 End: 11/19/09 Due: 11/19/10

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Phase: N/A Priority: Normal
NCT ID: NCT01149057 Org: User:
Start: 10/31/10 End: 07/31/14 Due: 07/31/15

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Phase: N/A Priority: Normal
NCT ID: NCT05181618 Org: User:
Start: 06/20/22 End: 05/21/27 Due: 05/21/28

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT01860638 Org: User:
Start: 08/19/13 End: 05/05/17 Due: 05/05/18

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT02611323 Org: User:
Start: 03/09/16 End: 08/04/22 Due: 08/04/23

A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma

Phase: N/A Priority: Normal
NCT ID: NCT01390948 Org: User:
Start: 10/18/11 End: 01/29/20 Due: 01/29/21

A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT01191983 Org: User:
Start: 08/13/10 End: 04/23/18 Due: 04/23/19

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

Phase: N/A Priority: Normal
NCT ID: NCT00643565 Org: User:
Start: 07/29/08 End: 04/30/19 Due: 04/30/20

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

Phase: N/A Priority: Normal
NCT ID: NCT02598453 Org: User:
Start: 01/31/05 End: 09/30/06 Due: 09/30/07

STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01367665 Org: User:
Start: 07/01/11 End: 06/14/17 Due: 06/14/18

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

Phase: N/A Priority: Normal
NCT ID: NCT00326963 Org: User:
Start: 03/31/06 End: 05/31/07 Due: 05/31/08

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Phase: N/A Priority: Normal
NCT ID: NCT01592305 Org: User:
Start: 05/31/12 End: 06/30/12 Due: 06/30/13

A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate

Phase: N/A Priority: Normal
NCT ID: NCT02528747 Org: User:
Start: 01/31/09 End: 12/31/11 Due: 12/31/12

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01046266 Org: User:
Start: 11/30/09 End: 06/30/12 Due: 06/30/13

A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism

Phase: N/A Priority: Normal
NCT ID: NCT02205073 Org: User:
Start: 07/31/14 End: 10/31/15 Due: 10/31/16

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT00718549 Org: User:
Start: 07/21/09 End: 09/14/15 Due: 09/14/16

A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.

Phase: N/A Priority: Normal
NCT ID: NCT00545402 Org: User:
Start: 11/30/07 End: 07/31/11 Due: 07/31/12

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Phase: N/A Priority: Normal
NCT ID: NCT00655473 Org: User:
Start: 03/31/08 End: 11/30/10 Due: 11/30/11

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT02814669 Org: User:
Start: 09/23/16 End: 07/31/19 Due: 07/31/20

A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine

Phase: N/A Priority: Normal
NCT ID: NCT00468754 Org: User:
Start: 07/31/03 End: 05/31/05 Due: 05/31/06